CHPA Plans Pharmacokinetic Trials On Pediatric OTC Cough/Cold Drugs

Companies are in discussions with FDA about conducting pharmacokinetic studies to confirm or refine pediatric cough/cold ingredient dosing in children age 2 to 12, according to the Consumer Healthcare Products Association

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet